Puberty Blockers Clinical Trial Debate
Full Debate: Read Full DebateDepartment: Department of Health and Social Care
Alex Sobel
Main Page: Alex Sobel (Labour (Co-op) - Leeds Central and Headingley)Department Debates - View all Alex Sobel's debates with the Department of Health and Social Care
(1 day, 12 hours ago)
Westminster HallRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.
Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Alex Sobel (Leeds Central and Headingley) (Lab/Co-op)
Many of my constituents have spoken or written to me because they are anxious about the pausing of the trial. In the words of one of my constituents,
“to be a true ally you must support all trans people and their needs, not just adults”.
As a matter of principle, politicians should not meddle in medical decisions. If we accept that trans people exist, and if they are to be accepted, they need to have access to healthcare. We must listen to the experiences of trans young people and take action to protect their wellbeing by opposing restrictions on gender-affirming care for trans youth. All children need access to safe and timely healthcare in line with international best practice. The pausing of the trial is causing deep anxiety among many of my constituents.
International best practice, as laid out by the World Professional Association for Transgender Health, emphasises that decisions around hormones should be made on a case-by-case basis. Puberty-suppressing hormones have long been used by children who experience early-onset puberty, and significant international research and advisory bodies already support their use by trans adolescents as a safe, reversible means of alleviating gender dysphoria and improving psychological functioning and wellbeing. They are used in Canada, Belgium, the Netherlands and many other European countries.
I have four asks of the Minister. Will the Department engage legitimately with the widest range of advocacy groups, including groups such as TransActual, to understand the real human impact of the ban and ensure that future policy is informed by those who are directly affected? Will the Department reinstate the trial, while ensuring that those who do not wish to take part in research can continue to access appropriate healthcare? Will the Department revise its policy on the prescription of gender-affirming hormones to remove arbitrary age limits, in line with international best practice? Will the Department do more to bring down waiting lists, which are more than six years for a first appointment at a young person’s gender service?
Like many, I am concerned about the erasure of the trans community. Today, we need to heed the many arguments they are making. In the words of the trans community, “Nothing about us without us.”